Prostate Biopsy Market

Executive Summary

Prostate Biopsy Market was valued at US $2.97 billion in 2021 and is projected to grow at 18.71% CAGR over the forecast period to reach US $8.31 billion by 2027. Prostate Biopsy Market represented US $0.86 billion opportunity over 2019-2021 and estimated to create US $5.34 billion opportunity in 2027 over 2021.

Prostate Biopsy from Consainsights analyses the Prostate Biopsy Market in the Life Sciences industry over the forecast period to 2027.

Prostate Biopsy research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Prostate Biopsy segmentation includes Type, End Users, Region and Geography.

Based on the Type, the Prostate Biopsy analysis covers PROSTATE NEEDLE BIOPSY, PROSTATE LIQUID BIOPSY.

In Type segment, PROSTATE NEEDLE BIOPSY segment has highest cagr growth of 16.47%.

Based on the End Users, the Prostate Biopsy analysis covers HOSPITALS, DIAGNOSTIC CENTRES, AMBULATORY SURGICAL CENTRES.

In End Users segment, HOSPITALS segment has highest cagr growth of 16.47%.

Based on the Region, the Prostate Biopsy analysis covers EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, EUROPE segment has highest cagr growth of 16.47%.

Based on the region, the Prostate Biopsy analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include C.R BARD INC, COOK, ENDO-MED TECHNOLOGICALS PVT LTD., SOMATEX MEDICAL TECHNOLOGIES GMBH, BOSTON SCIENTIFIC CORPORATION, ARGON MEDICAL DEVICES INC., PATHWAY GENOMICS, UROMED, UROTECH, EXOSOME DIAGNOSTCS and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, PROSTATE NEEDLE BIOPSY segment has the highest revenue of US $1.85 billion and is expected to grow at CAGR of 16.47% by 2027 PROSTATE NEEDLE BIOPSY segment has highest cagr growth of 16.47%.

PROSTATE NEEDLE BIOPSY

PROSTATE NEEDLE BIOPSY segment was valued at US $1.31 billion in 2019 and is projected to grow at 16.47% CAGR over the forecast period to reach US $5.18 billion by 2027. PROSTATE NEEDLE BIOPSY segment represented US $0.54 billion opportunity over 2019-2021 and estimated to create US $3.33 billion opportunity in 2027 over 2021.

PROSTATE LIQUID BIOPSY

PROSTATE LIQUID BIOPSY segment was valued at US $0.79 billion in 2019 and is projected to grow at 16.47% CAGR over the forecast period to reach US $3.13 billion by 2027. PROSTATE LIQUID BIOPSY segment represented US $0.32 billion opportunity over 2019-2021 and estimated to create US $2.01 billion opportunity in 2027 over 2021.

End Users

Introduction

In 2021, HOSPITALS segment has the highest revenue of US $1.76 billion and is expected to grow at CAGR of 16.47% by 2027 HOSPITALS segment has highest cagr growth of 16.47%.

HOSPITALS

HOSPITALS segment was valued at US $1.25 billion in 2019 and is projected to grow at 16.47% CAGR over the forecast period to reach US $4.93 billion by 2027. HOSPITALS segment represented US $0.51 billion opportunity over 2019-2021 and estimated to create US $3.17 billion opportunity in 2027 over 2021.

DIAGNOSTIC CENTRES

DIAGNOSTIC CENTRES segment was valued at US $0.79 billion in 2019 and is projected to grow at 16.47% CAGR over the forecast period to reach US $3.13 billion by 2027. DIAGNOSTIC CENTRES segment represented US $0.32 billion opportunity over 2019-2021 and estimated to create US $2.01 billion opportunity in 2027 over 2021.

AMBULATORY SURGICAL CENTRES

AMBULATORY SURGICAL CENTRES segment was valued at US $0.06 billion in 2019 and is projected to grow at 16.47% CAGR over the forecast period to reach US $0.25 billion by 2027. AMBULATORY SURGICAL CENTRES segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.16 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, ASIA-PACIFIC segment has the highest revenue of US $1.44 billion and is expected to grow at CAGR of 16.47% by 2027 EUROPE segment has highest cagr growth of 16.47%.

EUROPE

EUROPE segment was valued at US $0.88 billion in 2019 and is projected to grow at 16.47% CAGR over the forecast period to reach US $3.48 billion by 2027. EUROPE segment represented US $0.36 billion opportunity over 2019-2021 and estimated to create US $2.24 billion opportunity in 2027 over 2021.

ASIA-PACIFIC

ASIA-PACIFIC segment was valued at US $1.02 billion in 2019 and is projected to grow at 16.47% CAGR over the forecast period to reach US $4.03 billion by 2027. ASIA-PACIFIC segment represented US $0.42 billion opportunity over 2019-2021 and estimated to create US $2.59 billion opportunity in 2027 over 2021.

LAMEA

LAMEA segment was valued at US $0.20 billion in 2019 and is projected to grow at 16.47% CAGR over the forecast period to reach US $0.79 billion by 2027. LAMEA segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.51 billion opportunity in 2027 over 2021.